Vancomycin Study in Multiple Sclerosis (MS)

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.

Key facts

Study ID
NCT05539729
Run by
Icahn School of Medicine at Mount Sinai
People needed
12
Starts
2023-01-31
Expected to finish
2026-09-01
Last updated by the study team
2025-09-10

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.